Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.
TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSEhcp.com for the Full Prescribing Information.
REZLIDHIA (olutasidenib) capsules was approved in 2022. Please visit www.REZLIDHIAhcp.com for the Full Prescribing Information.